FILTER

Refine your search with the following facets to narrow down your results.

7 Current news of LEO Pharma

Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions

05-Dec-2018 - Evotec AG announced a new integrated drug discovery alliance with LEO Pharma. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s industry-leading hit ...

drug discovery Evotec skin diseases

LEO Pharma closes acquisition of Bayer’s prescription dermatology business in the United States

06-Sep-2018 - LEO Pharma and Bayer announced the completion of the relevant closing conditions to allow the transfer of Bayer’s prescription dermatology business to LEO Pharma in the United States. Closing in all other countries is expected during the second half of 2019, subject to the fulfillment of ...

acquisitions

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

26-May-2015 - arGEN-X N.V. and LEO Pharma A/S announced an alliance in which they will collaborate to develop antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions.Under the terms of the agreement, LEO Pharma receives exclusive access to an existing arGEN-X ...

chronic inflammation therapeutic antibodies

4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases

27-Feb-2013 - 4SC AG announced that its fully-owned research subsidiary 4SC Discovery GmbH has entered into an exclusive research and license agreement with LEO Pharma A/S, Ballerup, Denmark with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin ...

psoriasis

LEO Pharma unveils new scientific collaboration strategy

05-Oct-2012 - LEO Pharma has revealed plans to establish five long-term, strategic research collaborations from now until the end of 2013 in Australia, France, Germany and the US. The research will supplement LEO Pharma’s internal R&D activities.Each collaboration will integrate discovery research and ...

dermatology

Galapagos announces natural compounds collaboration with LEO Pharma

02-Nov-2006 - Galapagos NV announced a first collaboration with privately-held LEO Pharma. BioFocus DPI, Galapagos' service division, will use a subset of its natural compound collection for high throughput screening, hit verification, and profiling of selected compounds for LEO Pharma's antibacterial research ...

antibiotics BioFocus DPI Galapagos +1

Cougar Biotechnology Licenses Rights to Seocalcitol from LEO Pharma

01-Jul-2005 - Cougar Biotechnology, Inc announced that it has licensed the worldwide, exclusive rights to seocalcitol (EB1089) from LEO Pharma A/S (Ballerup, Denmark). Seocalcitol (EB1089) is a synthetic analog of vitamin D (1,25(OH2)D3) that has been clinically tested in a number of different cancer ...

clinical trials Denmark milestone payments +3